MK-6213

MK-6213 · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-6213, covering 2018-11-01 to 2018-11-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006) [Phase 2]

See pricing